Tg Therapeutics (TGTX) Cash & Current Investments (2011 - 2026)

Tg Therapeutics' Cash & Current Investments history runs 16 years deep, the most recent figure standing at $75.1 million for Q1 2026.

• In Q1 2026, Cash & Current Investments fell 72.82% year-over-year to $75.1 million; the TTM figure through Mar 2026 stood at $75.1 million (down 72.82% YoY), while the FY2025 annual figure was $64.1 million, down 51.21% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $75.1 million, up from $64.1 million in the prior quarter.
• The five-year high for Cash & Current Investments was $341.0 million in Q3 2024, with the low at $64.1 million in Q4 2025.
• The 5-year median for Cash & Current Investments is $209.8 million (2024), against an average of $194.1 million.
• The sharpest annual moves came in 2024 and 2026: Cash & Current Investments soared 50.16% in 2024, then sank 72.82% in 2026.
• Tg Therapeutics' Cash & Current Investments stood at $161.7 million in 2022, then soared by 34.53% to $217.5 million in 2023, then tumbled by 39.55% to $131.5 million in 2024, then slumped by 51.21% to $64.1 million in 2025, then rose by 17.05% to $75.1 million in 2026.
• Business Quant data shows TGTX's Cash & Current Investments at $75.1 million in Q1 2026, $64.1 million in Q4 2025, and $235.8 million in Q3 2025.